会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • MOLD STRUCTURE FOR MANUFACTURING OF SECURING FILM
    • 用于制造安全膜的模具结构
    • WO2008059999A1
    • 2008-05-22
    • PCT/KR2006/004750
    • 2006-11-13
    • LEE, Suk-chulKIM, Mi-youngUEDA, Minoru
    • LEE, Suk-chulKIM, Mi-youngUEDA, Minoru
    • B29C33/30B29C33/00
    • B29C33/301B29C51/225B29C53/265B29C2791/001
    • The present invention relates to a mold structure for manufacturing a securing film, and in particular, to a mold structure for manufacturing a securing film by alternately stacking and coupling two thin circular plates having different diameters from each other and allowing a concave structure to be formed within a transparent synthetic resin film which is closely adhered to outer circumferential surfaces of the two plates according to a height difference between the outer circumferential surface of the plate having the larger diameter and the outer circumferential surface of the plate having the smaller diameter, and a securing film which is accurately manufactured by filling the concave structure of the transparent synthetic resin film with a colored ink and coating on the resulting outer circumferential surface a transparent synthetic resin film such as a polyethylene terephthalate (PET).
    • 本发明涉及一种用于制造固定膜的模具结构,特别涉及用于通过交替地堆叠和耦合彼此不同直径的两个薄的圆形板来形成固定膜的模具结构,并且允许形成凹形结构 在根据具有较大直径的板的外周表面和具有较小直径的板的外周表面之间的高度差与两个板的外周表面紧密附着的透明合成树脂膜内, 通过将透明合成树脂膜的凹形结构用彩色油墨填充到所得到的外周面上,涂布诸如聚对苯二甲酸乙二醇酯(PET)等透明合成树脂膜,从而将其精确地制造。
    • 2. 发明公开
    • WOUND CONTRACTION INHIBITORS
    • Verwendung des sekretorischenleukozytären蛋白酶学家flo Keloide und Narben
    • EP1234581A1
    • 2002-08-28
    • EP00970076.6
    • 2000-10-25
    • Japan Tissue Engineering Co., Ltd.Ueda, Minoru
    • UEDA, MinoruSUMI, YukioHATA, KenichiroMURAMATSU, HisakoMURAMATSU, Takashi
    • A61K45/00A61K38/57A61K9/06A61K9/08A61P17/02
    • A61K38/57
    • The pharmaceutical formulation for inhibiting wound contraction of the present invention includes secretory leukocyte protease inhibitor as an active ingredient. The SLPI concentration in the pharmaceutical formulation is preferably 1 - 5000 ng/ml, and more preferably 1 - 100 ng/ml. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an external preparation including a base and the SLPI as an active ingredient. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an injection including the SLPI as an active ingredient. The external preparation may preferably include a preservative. The injection may preferably include a stabilizer (an antioxidant), a preservative and an analgesic agent.
    • 用于抑制本发明的伤口收缩的药物制剂包括分泌型白细胞蛋白酶抑制剂作为活性成分。 药物制剂中的SLPI浓度优选为1〜5000ng / ml,更优选为1〜100ng / ml。 用于抑制本发明的伤口收缩的药物制剂可以制备为包含底物和SLPI作为活性成分的外用制剂。 用于抑制本发明的伤口收缩的药物制剂可以制备为包含SLPI作为活性成分的注射剂。 外用制剂可优选包括防腐剂。 注射剂可以优选包括稳定剂(抗氧化剂),防腐剂和止痛剂。